[en] Although the therapeutic armamentarium of Inflammatory bowel diseases (IBD) physicians has expanded rapidly in recent years, a proportion of patients remain with a suboptimal response to medical treatment due to primary no response, loss of response or intolerance to currently available drugs. Our growing knowledges of IBD pathophysiology has led to the development of a multitude of new therapies over time, which may, 1 day, be able to address this unmet medical need. This review aims to provide physicians an update of emerging therapies in IBD by focusing on drugs currently in phase 3 clinical trials. Among the most promising molecules are anti-IL-23, JAK-inhibitors, anti-integrins and S1P modulators. While the results in terms of efficacy and safety are fairly clear for some classes, the question of safety remains more uncertain for other classes. Molecules at a more preliminary stage of development (phase 1 and 2), one of which may 1 day offer an optimal benefit-risk ratio, will also be presented as well as their respective mechanisms of action.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Vieujean, Sophie ; Centre Hospitalier Universitaire de Liège - CHU > > Service de gastroentérologie, hépatologie, onco. digestive
D'Amico, Ferdinando ; Department of Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy ; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy
Netter, Patrick; Université de Lorraine, CNRS, Laboratoire IMoPA, Nancy, France
Danese, Silvio; Department of Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy
Peyrin-Biroulet, Laurent ; Department of Gastroenterology, University of Lorraine, CHRU-Nancy, Nancy, France ; University of Lorraine, Inserm, NGERE, Nancy, France
Language :
English
Title :
Landscape of new drugs and targets in inflammatory bowel disease.
Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–9. https://doi.org/10.1016/S0140-6736(02)08512-4
Reinisch W, Sandborn WJ, Rutgeerts P, Feagan BG, Rachmilewitz D, Hanauer SB, et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis. 2012;18(2):201–11. https://doi.org/10.1002/ibd.21697
Karmiris K, Paintaud G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s disease. Gastroenterology. 2009;137(5):1628–40. https://doi.org/10.1053/J.GASTRO.2009.07.062
Lichtenstein GR, Thomsen O, Schreiber S, Lawrance IC, Hanauer SB, Bloomfield R, et al. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn’s disease for up to 18 months. Clin Gastroenterol Hepatol. 2010;8(7):600–9. https://doi.org/10.1016/J.CGH.2010.01.014
Reinisch W, Gibson PR, Sandborn WJ, Feagan BG, Strauss R, Johanns J, et al. Long-term benefit of golimumab for patients with moderately to severely active ulcerative colitis: results from the PURSUIT-maintenance extension. J Crohns Colitis. 2018;12(9):1053–66. https://doi.org/10.1093/ECCO-JCC/JJY079
Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel J.-F, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710. https://doi.org/10.1056/NEJMOA1215734
Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel J.-F, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(8):711–21. https://doi.org/10.1056/NEJMOA1215739
Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for crohn’s disease. N Engl J Med. 2016;375(20):1946–60. https://doi.org/10.1056/nejmoa1602773
Sandborn WJ, Su C, Sands BE, D’Haens GR, Vermeire S, Schreiber S, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723–36. https://doi.org/10.1056/nejmoa1606910
Feagan BG, Danese S, Loftus EV, Vermeire S, Schreiber S, Ritter T, et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021;397(10292):2372–84. https://doi.org/10.1016/S0140-6736(21)00666-8
Drug approval package: ZEPOSIA. n.d.
Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):644–59. https://doi.org/10.1038/ajg.2011.73
Ahern PP, Izcue A, Maloy KJ, Powrie F. The interleukin-23 axis in intestinal inflammation. Immunol Rev. 2008;226(1):147–59. https://doi.org/10.1111/j.1600-065X.2008.00705.x
Sands BE, Chen J, Feagan BG, Penney M, Rees WA, Danese S, et al. Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe crohn’s disease: a phase 2a study. Gastroenterology. 2017;153(1):77–86. e6. https://doi.org/10.1053/j.gastro.2017.03.049
Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650–61. https://doi.org/10.1016/S0140-6736(18)31713-6
Papp KA, Blauvelt A, Bukhalo M, Gooderham M, Krueger JG, Lacour J.-P, et al. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med. 2017;376(16):1551–60. https://doi.org/10.1056/nejmoa1607017
Feagan BG, Sandborn WJ, D’Haens G, Panés J, Kaser A, Ferrante M, et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2017;389(10080):1699–709. https://doi.org/10.1016/S0140-6736(17)30570-6
D’Haens G, Panaccione R, Baert F, Bossuyt P, Colombel J.-F, Danese S, et al. Risankizumab as induction therapy for Crohn’s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022;399(10340):2015–30. https://doi.org/10.1016/S0140-6736(22)00467-6
Feagan BG, Panés J, Ferrante M, Kaser A, D’Haens GR, Sandborn WJ, et al. Risankizumab in patients with moderate to severe Crohn’s disease: an open-label extension study. Lancet Gastroenterol Hepatol. 2018;3(10):671–80. https://doi.org/10.1016/S2468-1253(18)30233-4
Peyrin-Biroulet L, Louis E, Ghosh S, Lee SD, Griffith J, Wallace K, et al. S737 effect of risankizumab on patient-reported outcomes in patients with crohn’s disease with Inadequate response or intolerance to conventional and/or biologic treatments: results from phase 3 MOTIVATE and ADVANCE trials. Am J Gastroenterol. 2021;116(1):S338. https://doi.org/10.14309/01.ajg.0000776480.66336.75
Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, et al. Risankizumab as maintenance therapy for moderately to severely active Crohn’s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022;399(10340):2031–46. https://doi.org/10.1016/S0140-6736(22)00466-4
Schreiber SW, Cross R, Panaccione R, D’Haens G, Bossuyt P, Colombel JF, et al. DOP82 Achievement of steroid-free remission in patients with moderately to severely active Crohn’s Disease during treatment with risankizumab. J Crohn’s Colitis. 2022;16(Suppl 1):i125–6. https://doi.org/10.1093/ecco-jcc/jjab232.121
Atreya R, Feagan B, Shchukina O, Jairath V, Rieder F, Hisamatsu T, et al. DOP83 Normalisation of biomarkers and improvement in clinical outcomes in patients with Crohn’s Disease treated with risankizumab in the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies. J Crohn’s Colitis. 2022;16(Suppl 1):i126–7. https://doi.org/10.1093/ecco-jcc/jjab232.122
Feagan BG, Colombel JF, Panaccione R, Schreiber S, Ferrante M, Kamikozuru K, et al. P380 Early improvement of endoscopic outcomes with risankizumab is associated with reduced hospitalisation and surgery rates in patients with Crohn’s disease. J Crohn’s Colitis. 2022;16(Suppl 1):i381–2. https://doi.org/10.1093/ecco-jcc/jjab232.507
Ferrante M, Cao Q, Fujii T, Rausch A, Neimark E, Song A, et al. OP25 Patients with moderate to severe Crohn’s Disease with and without prior biologic failure demonstrate improved endoscopic outcomes with risankizumab: results from phase 3 induction and maintenance trials. J Crohn’s Colitis. 2022;16(Suppl 1):i027–8. https://doi.org/10.1093/ecco-jcc/jjab232.024
Peyrin-Biroulet L, Colombel JF, Louis E, Ferrante M, Motoya S, Panaccione R, et al. OP39 Shorter disease duration is associated with better outcomes in patients with moderately to severely active Crohn’s Disease treated with risankizumab: results from the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies. J Crohn’s Colitis. 2022;16(Suppl 1):i045–8. https://doi.org/10.1093/ecco-jcc/jjab232.038
Bossuyt P, Bresso F, Dubinsky M, Ha C, Siegel C, Zambrano J, et al. OP40 Efficacy of risankizumab induction and maintenance therapy by baseline Crohn’s Disease location: post hoc analysis of the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies. J Crohn’s Colitis. 2022;16(Suppl 1):i048. https://doi.org/10.1093/ecco-jcc/jjab232.039
D’Haens G, Beaton M, Bossuyt P, Dotan I, Sands B, Sugimoto K, et al. P544 Patients with moderate to severe Crohn’s disease with and without prior biologic failure demonstrated improved clinical outcomes with risankizumab: results from phase 3 induction and maintenance trials. J Crohn’s Colitis. 2022;16(Suppl 1):i491. https://doi.org/10.1093/ecco-jcc/jjab232.671
Alsoud D, Franchimont D, D’Heygere F, Bossuyt P, Vijverman A, Van Hootegem P, et al. P576 Real-world effectiveness and safety of risankizumab in patients with moderate-to-severe multi-refractory Crohn’s disease: a Belgian multi-centric cohort study. J Crohn’s Colitis. 2022;16(Suppl 1):i516–7. https://doi.org/10.1093/ECCO-JCC/JJAB232.702
Study comparing intravenous (IV)/Subcutaneous (SC) risankizumab to IV/SC ustekinumab to assess change in Crohn’s disease activity index (CDAI) in adult participants with moderate to severe Crohn’s disease (CD) - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT04524611?cond=NCT04524611%26draw=2%26rank=1. Accessed 11 July 2022.
Biotech J. Tremfya (Guselkumab)[package insert]. US Food and drug administration website; 2019. https://scholar.google.com/scholar_lookup?title=TREMFYA+(guselkumab)+[package+insert]%26publication_year=2017%26#d=gs_cit%26t=1657662929381%26u=%2Fscholar%3Fq%3Dinfo%3AhYS8EktFiyQJ%3Ascholar.google.com%2F%26output%3Dcite%26scirp%3D0%26hl%3Dfr. Accessed 12 July 2022.
Boehncke WH, Brembilla NC, Nissen MJ. Guselkumab: the first selective IL-23 inhibitor for active psoriatic arthritis in adults. Expert Rev Clin Immunol. 2021;17(1):5–13. https://doi.org/10.1080/1744666X.2020.1857733
Sandborn WJ, D’Haens GR, Reinisch W, Panés J, Chan D, Gonzalez S, et al. Guselkumab for the treatment of crohn’s disease: induction results from the phase 2 GALAXI-1 study. Gastroenterology. 2022;162(6):1650–64. e8. https://doi.org/10.1053/j.gastro.2022.01.047
Danese S, Panaccione R, Rubin DT, Sands BE, Reinisch W, D’Haens G, et al. OP24 Clinical efficacy and safety of guselkumab maintenance therapy in patients with moderately to severely active Crohn’s Disease: week 48 analyses from the phase 2 GALAXI 1 study. J Crohn’s Colitis. 2022;16(Suppl 1):i026–7. https://doi.org/10.1093/ecco-jcc/jjab232.023
Dignass A, Rubin D, Bressler B, Huang KH, Shipitofsky N, Germinaro M, et al. OP23 the efficacy and safety of guselkumab induction therapy in patients with moderately to severely active Ulcerative Colitis: phase 2b QUASAR Study results through week 12. J Crohn’s Colitis. 2022;16(Suppl 1):i025–6. https://doi.org/10.1093/ecco-jcc/jjab232.022
A study of guselkumab subcutaneous therapy in participants with moderately to severely active Crohn’s disease - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT05197049?cond=NCT05197049%26draw=2%26rank=1. Accessed 11 July 2022.
A study of guselkumab in participants with fistulizing, perianal Crohn’s disease (FUZION CD). https://www.clinicaltrials.gov/ct2/show/NCT05347095?cond=NCT05347095%26draw=2%26rank=1. Accessed 11 July 2022.
Köck K, Pan WJ, Gow JM, Horner MJ, Gibbs JP, Colbert A, et al. Preclinical development of AMG 139, a human antibody specifically targeting IL-23. Br J Pharmacol. 2015;172(1):159–72. https://doi.org/10.1111/bph.12904
An active and placebo-controlled study of brazikumab in participants with moderately to severely active Crohn’s disease (INTREPID). https://www.clinicaltrials.gov/ct2/show/NCT03759288?cond=NCT03759288%26draw=2%26rank=1. Accessed 11 July 2022.
Placebo-controlled study of brazikumab in participants with moderately to severely active ulcerative colitis (expedition). https://www.clinicaltrials.gov/ct2/show/NCT03616821?cond=NCT03616821%26draw=2%26rank=1. Accessed 11 July 2022.
D’Haens G, Kobayashi T, Morris N, Lissoos T, Hoover A, Li X, et al. 884: efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active ulcerative colitis: results from the phase 3 LUCENT-1 study. Gastroenterology. 2022;162(7):S-214–14. https://doi.org/10.1016/S0016-5085(22)60513-4
Dubinsky MC, Irving PM, Li X, Howaldt S, Pokrotnieks J, Krueger KA, et al. 867e: efficacy and safety of mirikizumab as maintenance theraoy in patients with moderately to severely active ulcerative colitis: results from the phase 3 LUCENT-2 study. Gastroenterology. 2022;162(7):S-1393–S-1394. https://doi.org/10.1016/S0016-5085(22)64060-5
Sands BE, Sandborn WJ, Peyrin-Biroulet L, Higgins PD, Hirai F, Belin R, et al. 1003 – efficacy and safety of mirikizumab (LY3074828) in a phase 2 study of patients with crohn’s disease. Gastroenterology. 2019;156(6):S-216–16. https://doi.org/10.1016/s0016-5085(19)37335-4
A study to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (LUCENT 3). https://clinicaltrials.gov/ct2/show/NCT03519945?cond=Mirikizumab%26draw=3%26rank=13. Accessed 12 July 2022.
A study of mirikizumab (LY3074828) in participants with Crohn’s disease (VIVID-1). https://clinicaltrials.gov/ct2/show/NCT03926130?cond=Mirikizumab%26draw=2%26rank=6. Accessed 12 July 2022.
A long-term extension study of mirikizumab (LY3074828) in participants with Crohn’s disease (VIVID-2). https://clinicaltrials.gov/ct2/show/NCT04232553?cond=Mirikizumab%26draw=2%26rank=8. Accessed 12 July 2022.
Sandborn WJ, Ferrante M, Bhandari BR, Berliba E, Feagan BG, Hibi T, et al. Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis. Gastroenterology. 2020;158(3):537–49. e10. https://doi.org/10.1053/j.gastro.2019.08.043
Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. JAK–STAT signaling as a target for inflammatory and Autoimmune diseases: current and future prospects. Drugs. 2017;77(5):521–46. https://doi.org/10.1007/s40265-017-0701-9
Salas A, Hernandez-Rocha C, Duijvestein M, Faubion W, McGovern D, Vermeire S, et al. JAK–STAT pathway targeting for the treatment of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020;17(6):323–37. https://doi.org/10.1038/s41575-020-0273-0
Langrish CL, McKenzie BS, Wilson NJ, De Waal Malefyt R, Kastelein RA, Cua DJ. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev. 2004;202(1):96–105. https://doi.org/10.1111/j.0105-2896.2004.00214.x
Parigi TL, Solitano V, Peyrin-Biroulet L, Danese S. Do JAK inhibitors have a realistic future in treating Crohn’s disease? Expert Rev Clin Immunol. 2022;18:181–3. https://doi.org/10.1080/1744666X.2022.2020101
Panés J, Sandborn WJ, Schreiber S, Sands BE, Vermeire S, D’Haens G, et al. Tofacitinib for induction and maintenance therapy of Crohn’s disease: results of two phase IIb randomised placebo-controlled trials. Gut. 2017;66(6):1049–59. https://doi.org/10.1136/gutjnl-2016-312735
Rogler G. Efficacy of JAK inhibitors in crohn’s disease. J Crohns Colitis. 2020;14(Suppl 2):S746–54. https://doi.org/10.1093/ecco-jcc/jjz186
Vermeire S, Schreiber S, Petryka R, Kuehbacher T, Hebuterne X, Roblin X, et al. Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017;389(10066):266–75. https://doi.org/10.1016/S0140-6736(16)32537-5
Reinisch W, Colombel JF, D’Haens GR, Rimola J, DeHaas-Amatsaleh A, McKevitt M, et al. OP18 Efficacy and safety of filgotinib for the treatment of perianal fistulizing Crohn’s Disease: results from the phase 2 DIVERGENCE 2 study. J Crohn’s Colitis. 2022;16(Suppl 1):i019–21. https://doi.org/10.1093/ecco-jcc/jjab232.017
Filgotinib in the induction and maintenance of remission in adults with moderately to severely active Crohn’s disease - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT02914561?cond=filgotinib+CRohn%26draw=2%26rank=2. Accessed 10 July 2022.
Filgotinib in long-term extension study of adults with Crohn’s disease - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT02914600?cond=filgotinib+CRohn%26draw=2%26rank=1. Accessed 10 July 2022.
Sandborn WJ, Ghosh S, Panes J, Schreiber S, D’Haens G, Tanida S, et al. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis. Gastroenterology. 2020;158(8):2139–49. e14. https://doi.org/10.1053/j.gastro.2020.02.030
Danese S, Vermeire S, Zhou W, Pangan AL, Siffledeen J, Greenbloom S, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399(10341):2113–28. https://doi.org/10.1016/S0140-6736(22)00581-5
Higgins P, Colombel JF, Reguiero M, Parkes G, Ilo D, Philips C, et al. DOP39 Effect of baseline disease characteristics on clinical outcomes in moderate-to-severe Ulcerative Colitis treated with upadacitinib: results from a Phase 3 trials programme. J Crohn’s Colitis. 2022;16(Suppl 1):i088–9. https://doi.org/10.1093/ecco-jcc/jjab232.078
Sandborn WJ, Feagan BG, Loftus EV, Peyrin-Biroulet L, Van Assche G, D’Haens G, et al. Efficacy and safety of upadacitinib in a randomized trial of patients with crohn’s disease. Gastroenterology. 2020;158(8):2123–38. e8. https://doi.org/10.1053/j.gastro.2020.01.047
Peyrin-Biroulet L, Danese S, Louis E, Higgins PD, Dubinsky M, Cataldi F, et al. Mo1837 – effect of upadacitinib on extra-intestinal manifestations in patients with moderate to severe crohn’s disease: data from the celest study. Gastroenterology. 2019;156(6):S-856. https://doi.org/10.1016/s0016-5085(19)39104-8
A multicenter, randomized, double-blind, placebo-controlled study of ABT-494 for the induction of symptomatic and endoscopic remission in subjects with moderately to severely active Crohn’s disease who have inadequately responded to or are intolerant to I. https://www.clinicaltrials.gov/ct2/show/NCT02365649?cond=NCT02365649%26draw=2%26rank=1. Accessed 11 July 2022.
Pokryszka J, Reinisch S, Primas C, Novacek G, Reinisch W. Induction efficacy of upadacitinib in therapy-refractory crohn’s disease: a retrospective case series. Clin Gastroenterol Hepatol. 2022. https://doi.org/10.1016/j.cgh.2022.01.004
Traboulsi C, Ayoub F, Silfen A, Rodriguez TG, Rubin DT. Upadacitinib is safe and effective for crohn’s disease: real-world data from a tertiary center. Dig Dis Sci. 2022. https://doi.org/10.1007/s10620-022-07582-w
Clinicaltrials.gov. A study of the efficacy and safety of upadacitnib (ABT-494) in participants with moderately to severely active Crohn’s disease who have inadequately responded to or are intolerant to conventional and/or biologic therapies. NCT03345849. https://www.clinicaltrials.gov/ct2/show/NCT03345849?cond=upadacitinib+Crohn%26draw=2%26rank=4. Accessed 10 July 2022.
A maintenance and long-term extension study of the efficacy and safety of upadacitinib (ABT-494) in participants with Crohn’s disease who completed the studies M14-431 or M14-433 - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT03345823?cond=upadacitinib+Crohn%26draw=2%26rank=2. Accessed 10 July 2022.
AbbVie A. Study of the efficacy and safety of upadacitinib (ABT-494) in participants with moderately to severely active Crohn’s disease who have inadequately responded to or are intolerant to biologic therapy - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT03345836?cond=upadacitinib+Crohn%26draw=2%26rank=1. Accessed 10 July 2022.
A study to evaluate the long-term efficacy, safety, and tolerability of repeated administration of upadacitinib (ABT-494) in participants with Crohn’s disease. https://www.clinicaltrials.gov/ct2/show/NCT02782663?cond=A+Study+to+Evaluate+the+Long-Term+Efficacy%2C+Safety%2C+and+Tolerability+of+Repeated+Administration+of+Upadacitinib+%28ABT-494%29+in+Participants+With+Crohn%27s+Disease%26draw=2%26rank=1. Accessed 11 July 2022.
A study to evaluate the long-term safety and efficacy of upadacitinib (ABT-494) in participants with ulcerative colitis (UC) - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT03006068?cond=upadacitinib+ulcerative+colitis%26draw=2%26rank=3. Accessed 10 July 2022.
Nct A. Phase II study in patients with moderate to severe active ulcerative colitis. https://ClinicaltrialsGov/Show/NCT03675477%202018
Biopharma R. A phase II study in patients with moderate to severe active ulcerative colitis - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT03675477?cond=NCT03675477%26draw=2%26rank=1. Accessed 9 July 2022.
Chen B, Zhong J, Cao Q, Li X, Pan F, Li S, et al. 775c A phase 2 randomized controlled trial demonstrating the efficacy and safety of Shr0302, A selective JAK1 inhibitor for the treatment of moderate to severe ulcerative colitis patients. Gastroenterology. 2021;161(2):e29–30. https://doi.org/10.1053/j.gastro.2021.06.039
A phase 3 study to investigate the efficacy and safety of SHR0302 with moderately to severely active ulcerative colitis - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT05181137?cond=SHR0302%26draw=2%26rank=8. Accessed 9 July 2022.
Ma C, Lee JK, Mitra AR, Teriaky A, Choudhary D, Nguyen TM, et al. Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease. Aliment Pharmacol Ther. 2019;50(1):5–23. https://doi.org/10.1111/apt.15297
Vermeire S, Colombel JF, Takeuchi K, Gao X, Panaccione R, Danese S, et al. DOP38 upadacitinib therapy reduces ulcerative colitis symptoms as early as day 1. J Crohn’s Colitis. 2022;16(Suppl 1):i087–8. https://doi.org/10.1093/ecco-jcc/jjab232.077
Lasa JS, Olivera PA, Danese S, Peyrin-Biroulet L. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(2):161–70. https://doi.org/10.1016/S2468-1253(21)00377-0
Burr NE, Gracie DJ, Black CJ, Ford AC. Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis. Gut. 2021;0:326390–326390. https://doi.org/10.1136/gutjnl-2021-326390
Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316–26. https://doi.org/10.1056/nejmoa2109927
Solitano V, Fiorino G, D’Amico F, Peyrin-Biroulet L, Danese S. Thrombosis in IBD in the era of JAK inhibition. Curr Drug Targets. 2021;22(1):126–36. https://doi.org/10.2174/1389450121666200902164240
Fumery M, Xiaocang C, Dauchet L, Gower-Rousseau C, Peyrin-Biroulet L, Colombel JF. Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies. J Crohn’s Colitis. 2014;8(6):469–79. https://doi.org/10.1016/j.crohns.2013.09.021
Olivera PA, Lasa JS, Bonovas S, Danese S, Peyrin-Biroulet L. Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology. 2020;158(6):1554–73. e12. https://doi.org/10.1053/j.gastro.2020.01.001
D’Haens G, Panés J, Louis E, Lacerda A, Zhou Q, Liu J, et al. Upadacitinib was efficacious and well-tolerated over 30 Months in patients with crohn’s disease in the CELEST extension study. Clin Gastroenterol Hepatol. 2022. https://doi.org/10.1016/j.cgh.2021.12.030
Nv G. Galapagos reports primary endpoint for the ongoing filgotinib manta and manta-ray safety studies. GlobeNewswire News Room; 2021. Available at: https://www.globenewswire.com/news-release/2021/03/04/2186756/0/en/GALAPAGOS-REPORTS-PRIMARY-ENDPOINT-FOR-Thttps://www.globenewswire.com/news-release/2021/03/04/2186756/0/en/GALAPAGOS-REPORTS-PRIMARY-ENDPOINT-FOR-THE-ONGOING-FILGOTINIB-MANTA-AND-MANTA-RAy-SAFETY-STUDIES.html. Accessed 13 July 2022.
Sun H, Liu J, Zheng YJ, Pan YD, Zhang K, Chen JF. Distinct chemokine signaling regulates integrin ligand specificity to dictate tissue-specific lymphocyte homing. Dev Cell. 2014;30(1):61–70. https://doi.org/10.1016/j.devcel.2014.05.002
Limited TPC. European commission releases Takeda from commitment to divest Shire’s pipeline compound SHP647. https://www.takeda.com/newsroom/newsreleases/2020/european-commission-releases-takeda-from-commitment-to-divest--shires-pipeline-compound-shp647/. Accessed 12 July 2022.
Danese S, Colombel JF, Lukas M, Gisbert JP, D’Haens G, Hayee B, et al. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. Lancet Gastroenterol Hepatol. 2022;7(2):118–27. https://doi.org/10.1016/S2468-1253(21)00294-6
Matsuoka K, Watanabe M, Ohmori T, Nakajima K, Ishida T, Ishiguro Y, et al. AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Gastroenterol Hepatol. 2022;7(7):648–57. https://doi.org/10.1016/S2468-1253(22)00022-X
EA Pharma Co L. A study to evaluate the safety and efficacy of AJM300 in participants with active ulcerative colitis. ClinicalTrials.Gov. https://www.clinicaltrials.gov/ct2/show/NCT03531892?cond=AJM300+ulcerative%26draw=2%26rank=1. Accessed 10 July 2022.
Peyrin-Biroulet L, Hart A, Bossuyt P, Long M, Allez M, Juillerat P, et al. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. Lancet Gastroenterol Hepatol. 2022;7(2):128–40. https://doi.org/10.1016/S2468-1253(21)00298-3
Vermeire S, Lakatos PL, Ritter T, Hanauer S, Bressler B, Khanna R, et al. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. Lancet Gastroenterol Hepatol. 2022;7(1):28–37. https://doi.org/10.1016/S2468-1253(21)00295-8
Rubin DT, Dotan I, DuVall A, Bouhnik Y, Radford-Smith G, Higgins PDR, et al. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. Lancet Gastroenterol Hepatol. 2022;7(1):17–27. https://doi.org/10.1016/S2468-1253(21)00338-1
Clinical Trials Identifier NCT02171429. Study for participants with ulcerative colitis previously enrolled in etrolizumab phase II/III studies - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT02118584?cond=etrolizumab+ulcerative+colitis%26draw=2%26rank=1. Accessed 10 July 2022.
NCT03478956. A phase I study of etrolizumab followed by open-label extension and safety monitoring in pediatric patients with moderate to severe ulcerative colitis or moderate to severe Crohn’s disease. https://ClinicaltrialsGov/Show/Nct03478956%202018
Sandborn WJ, Vermeire S, Tyrrell H, Hassanali A, Lacey S, Tole S, et al. Etrolizumab for the treatment of ulcerative colitis and crohn’s disease: an overview of the phase 3 clinical program. Adv Ther. 2020;37(7):3417–31. https://doi.org/10.1007/s12325-020-01366-2
Open-label extension and safety study for participants with Crohn’s disease previously enrolled in the etrolizumab phase III study GA29144 - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT02403323?cond=etrolizumab+crohn%26draw=2%26rank=1. Accessed 10 July 2022.
Yoshimura N, Watanabe M, Motoya S, Tominaga K, Matsuoka K, Iwakiri R, et al. Safety and efficacy of AJM300, an oral antagonist of α4 integrin, in induction therapy for patients with active ulcerative colitis. Gastroenterology. 2015;149(7):1775–83. e2. https://doi.org/10.1053/j.gastro.2015.08.044
Park SC, Jeen YT. Anti-integrin therapy for inflammatory bowel disease. World J Gastroenterol. 2018;24(17):1868–80. https://doi.org/10.3748/wjg.v24.i17.1868
Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science. 2002;296(5566):346–9. https://doi.org/10.1126/science.1070238
Marsolais D, Rosen H. Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules. Nat Rev Drug Discov. 2009;8(4):297–307. https://doi.org/10.1038/nrd2356
Sandborn WJ, Feagan BG, D’Haens G, Wolf DC, Jovanovic I, Hanauer SB, et al. Ozanimod as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2021;385(14):1280–91. https://doi.org/10.1056/nejmoa2033617
Cohen NA, Choi D, Choden T, Cleveland NK, Cohen RD, Rubin DT. Ozanimod in the treatment of ulcerative colitis: Initial real-world data from a large tertiary center. Clin Gastroenterol Hepatol. 2022. https://doi.org/10.1016/j.cgh.2022.03.035
Feagan BG, Sandborn WJ, Danese S, Wolf DC, Liu WJ, Hua SY, et al. Ozanimod induction therapy for patients with moderate to severe Crohn’s disease: a single-arm, phase 2, prospective observer-blinded endpoint study. Lancet Gastroenterol Hepatol. 2020;5(9):819–28. https://doi.org/10.1016/S2468-1253(20)30188-6
An extension study of RPC1063 as therapy for moderate to severe ulcerative colitis. https://www.clinicaltrials.gov/ct2/show/NCT02531126?cond=Ozanimod+ulcerative+colitis%26draw=2%26rank=3. Accessed 11 July 2022.
Safety and efficacy trial of RPC1063 for moderate to severe ulcerative colitis. https://www.clinicaltrials.gov/ct2/show/NCT02435992?cond=Ozanimod+ulcerative+colitis%26draw=2%26rank=4. Accessed 11 July 2022.
To evaluate efficacy and long-term safety of ozanimod in Japanese subjects with moderately to severely active ulcerative colitis. https://www.clinicaltrials.gov/ct2/show/NCT03915769?cond=Ozanimod+ulcerative+colitis%26draw=2%26rank=5. Accessed 11 July 2022.
An extension study of oral ozanimod for moderately to severely active Crohn’s disease. https://www.clinicaltrials.gov/ct2/show/NCT03467958?cond=ozanimod+crohn%26draw=2%26rank=1. Accessed 11 July 2022.
A placebo-controlled study of oral ozanimod as maintenance therapy for moderately to severely active Crohn’s disease. https://www.clinicaltrials.gov/ct2/show/NCT03464097?cond=ozanimod+crohn%26draw=2%26rank=2. Accessed 11 July 2022.
Induction study #2 of oral ozanimod as induction therapy for moderately to severely active Crohn’s disease. https://www.clinicaltrials.gov/ct2/show/NCT03440385?cond=ozanimod+crohn%26draw=2%26rank=3. Accessed 11 July 2022.
Induction study #1 of oral ozanimod as induction therapy for moderately to severely active Crohn’s disease. https://www.clinicaltrials.gov/ct2/show/NCT03440372?cond=ozanimod+crohn%26draw=2%26rank=4. Accessed 11 July 2022.
A study investigating oral ozanimod (RPC1063) in pediatric participants with moderate to severe active ulcerative colitis. https://www.clinicaltrials.gov/ct2/show/NCT05076175?cond=Ozanimod+ulcerative+colitis%26draw=2%26rank=2. Accessed 11 July 2022.
Sandborn WJ, Peyrin-Biroulet L, Zhang J, Chiorean M, Vermeire S, Lee SD, et al. Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis. Gastroenterology. 2020;158(3):550–61. https://doi.org/10.1053/j.gastro.2019.10.035
Vermeire S, Chiorean M, Panés J, Peyrin-Biroulet L, Zhang J, Sands BE, et al. Long-term safety and efficacy of etrasimod for ulcerative colitis: results from the open-label extension of the OASIS study. J Crohn’s Colitis. 2021;15(6):950–9. https://doi.org/10.1093/ecco-jcc/jjab016
Etrasimod versus placebo for the treatment of moderately active ulcerative colitis - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT04607837?cond=NCT04607837%26draw=2%26rank=1. Accessed 10 July 2022.
Nct. Oral etrasimod versus placebo for the treatment of moderately to severely active ulcerative colitis in adult Japanese participants (ELEVATE UC 40 JAPAN). https://ClinicaltrialsGov/Show/NCT04706793%202021
Kernel Networks Inc. Etrasimod versus placebo for the treatment of moderately to severely active ulcerative colitis. Case Med Res. 2019. https://doi.org/10.31525/ct1-nct03945188
An extension study for treatment of moderately to severely active ulcerative colitis - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT03950232?cond=NCT03950232%26draw=2%26rank=1. Accessed 10 July 2022.
Etrasimod versus placebo as induction therapy in moderately to severely active ulcerative colitis - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT03996369?cond=NCT03996369%26draw=2%26rank=1. Accessed 10 July 2022.
A study evaluating the efficacy and safety of oral etrasimod in the treatment of adult participants with moderately to severely active Crohn’s disease - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT04173273?cond=etrasimod+crohn%26draw=2%26rank=1. Accessed 10 July 2022.
Sriwastava S, Chaudhary D, Srivastava S, Beard K, Bai X, Wen S, et al. Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature. J Neurol. 2022;269(3):1678–87. https://doi.org/10.1007/s00415-021-10910-1
Atreya R, Bloom S, Scaldaferri F, Gerardi V, Admyre C, Karlsson Å, et al. Clinical effects of a topically applied toll-like receptor 9 agonist in active moderate-to-severe ulcerative colitis. J Crohn’s Colitis. 2016;10(11):1294–302. https://doi.org/10.1093/ecco-jcc/jjw103
Atreya R, Reinisch W, Peyrin-Biroulet L, Scaldaferri F, Admyre C, Knittel T, et al. Clinical efficacy of the Toll-like receptor 9 agonist cobitolimod using patient-reported-outcomes defined clinical endpoints in patients with ulcerative colitis. Dig Liver Dis. 2018;50(10):1019–29. https://doi.org/10.1016/j.dld.2018.06.010
The efficacy and safety of cobitolimod in participants with moderate to severe active left-sided ulcerative colitis (CONCLUDE). https://www.clinicaltrials.gov/ct2/show/NCT04985968?cond=NCT04985968%26draw=2%26rank=1. Accessed 10 July 2022.
Schmitt H, Ulmschneider J, Billmeier U, Vieth M, Scarozza P, Sonnewald S, et al. The TLR9 agonist cobitolimod induces IL10-producing wound healing macrophages and regulatory T cells in ulcerative colitis. J Crohn’s Colitis. 2020;14(4):508–24. https://doi.org/10.1093/ecco-jcc/jjz170
Abreu MT. Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nat Rev Immunol. 2010;10(2):131–43. https://doi.org/10.1038/nri2707
olitis - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT05377580?cond=IBI112%26draw=2%26rank=1. Accessed 10 July 2022.
Safety and efficacy of TJ301 IV in participants with active ulcerative colitis - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT03235752?cond=TJ301%26draw=2%26rank=1. Accessed 10 July 2022.
NCT01287897. A study to assess the efficacy and safety of PF-04236921 in subjects with Crohn’s disease who failed anti-TNF therapy. https://ClinicaltrialsGov/Show/Nct01287897%202011
Biopharma R. Study of OSE-127 vs placebo in patients with moderate to severe active ulcerative colitis - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT05177835?cond=ABX464%26draw=2%26rank=11. Accessed 9 July 2022.
Euctr GB. A clinical trial of antibody GSK1070806 in the treatment of patients with moderate to severe Crohna[Euro sign][TM]s Disease. https://TrialsearchWhoInt/Trial2Aspx?TrialID=EUCTR2018%202018
A randomised, double-blind, placebo-controlled, parallel-group trial to assess clinical efficacy and safety of NNC0114-0006 in subjects with active Crohn’s disease - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT01751152?cond=NNC0114-0006%26draw=2%26rank=3. Accessed 10 July 2022.
BI655130 (SPESOLIMAB) induction treatment in patients with moderate-to-severe ulcerative colitis - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT03482635?cond=Spesolimab%26draw=1%26rank=8. Accessed 10 July 2022.
BI 655130 long-term treatment in patients with moderate-to severe ulcerative colitis - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT03648541?cond=Spesolimab%26draw=1%26rank=11. Accessed 10 July 2022.
A study of LY3471851 in adult participants with moderately to severely active ulcerative colitis (UC) - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT04677179?cond=LY3471851%26draw=2%26rank=6. Accessed 10 July 2022.
Safety and efficacy of efavaleukin alfa in participants with moderately to severely active ulcerative colitis - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT04987307?cond=efavaleukin+alfa%26draw=2%26rank=1. Accessed 10 July 2022.
Study of efavaleukin alfa in healthy Chinese, Japanese, and caucasian participants - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT04987333?cond=efavaleukin+alfa%26draw=2%26rank=6. Accessed 10 July 2022.
European Crohn´s and Colitis Organisation - ECCO - P294 AMT-101, a gut selective oral IL-10 fusion: results from a Phase 1b study in patients with active Ulcerative Colitis. https://www.ecco-ibd.eu/publications/congress-abstracts/item/p294-amt-101-a-gut-selective-oral-il-10-fusion-results-from-a-phase-1b-study-in-patients-with-active-ulcerative-colitis.html. Accessed 13 July 2022.
Wagner F, Mansfield J, Geier C, Dash A, Wang Y, Li C, et al. P420 A randomised, observer-blinded phase Ib multiple, ascending dose study of UTTR1147A, an IL-22Fc fusion protein, in healthy volunteers and ulcerative colitis patients. J Crohn’s Colitis. 2020;14(Suppl 1):S382–3. https://doi.org/10.1093/ecco-jcc/jjz203.549
Study to compare oral PF-06651600, PF-06700841 and placebo in subjects with moderate to severe ulcerative colitis - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT02958865?cond=PF-06700841%26draw=2%26rank=13. Accessed 10 July 2022.
Study to evaluate the efficacy and safety of oral PF-06651600 and PF-06700841 in subjects with moderate to severe Crohn’s disease - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT03395184?cond=PF-06700841%26draw=2%26rank=14. Accessed 10 July 2022.
A Study of the Safety, efficacy, and biomarker response of BMS-986165 in participants with moderate to severe ulcerative colitis - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT04613518?cond=BMS-986165%26draw=2%26rank=19. Accessed 10 July 2022.
Safety and efficacy of deucravacitinib in participants with moderate to severe ulcerative colitis - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT03934216?cond=BMS-986165%26draw=2%26rank=41. Accessed 10 July 2022.
A study to evaluate the long-term safety and efficacy of deucravacitinib in participants with Crohn’s disease or ulcerative colitis - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT04877990?cond=BMS-986165%26draw=2%26rank=44. Accessed 10 July 2022.
Study of OST-122 in patients with moderate to severe ulcerative colitis - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT04353791?cond=OST-122%26draw=2%26rank=1. Accessed 10 July 2022.
A study of safety and effectiveness of JNJ-54781532 in patients with moderately to severely active ulcerative colitis - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT01959282?cond=JNJ-54781532%26draw=2%26rank=1. Accessed 10 July 2022.
Sandborn WJ, Cyrille M, Hansen MB, Feagan BG, Loftus EV, Rogler G, et al. Efficacy and safety of abrilumab in a randomized, placebo-controlled trial for moderate-to-severe ulcerative colitis. Gastroenterology. 2019;156(4):946–57. e18. https://doi.org/10.1053/j.gastro.2018.11.035
Abrilumab (AMG 181) in adults with moderate to severe ulcerative colitis - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT01694485?cond=AMG181%26draw=2%26rank=2. Accessed 10 July 2022.
Abrilumab (AMG 181) in adults with moderate to severe Crohn’s disease - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT01696396?cond=AMG181%26draw=2%26rank=1. Accessed 10 July 2022.
European Crohn´s and Colitis Organisation - ECCO - P004 PN-943, an oral α4β7 integrin antagonist, inhibits MAdCAM1-mediated proliferation and cytokine release from CD4+ T cells independent of trafficking. https://www.ecco-ibd.eu/publications/congress-abstracts/item/p004-pn-943-an-oral-0945-4-0946-7-integrin-antagonist-inhibits-madcam1-mediated-proliferation-and-cytokine-release-from-cd4-0043-t-cells-independent-of-trafficking.html. Accessed 13 July 2022.
D’Haens G, Danese S, Davies M, Watanabe M, Hibi T. A phase II, multicentre, randomised, double-blind, placebo-controlled study to evaluate safety, tolerability, and efficacy of Amiselimod in patients with moderate to severe active crohn’s disease. J Crohn’s Colitis. 2021;16(5):746–56. https://doi.org/10.1093/ecco-jcc/jjab201
Radeke HH, Stein J, Van Assche G, Rogler G, Lakatos PL, Muellershausen F, et al. A multicentre, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of the S1P receptor agonist KRP203 in patients with moderately active refractory ulcerative colitis. Inflamm Intest Dis. 2020;5(4):180–90. https://doi.org/10.1159/000509393
A study assessing the efficacy and safety of CBP-307 in subjects with moderate to severe ulcerative colitis (UC) - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT04700449?cond=CBP-307%26draw=2%26rank=2. Accessed 10 July 2022.
Efficacy & safety in moderately active refractory ulcerative colitis patients - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT01375179?cond=KRP203%26draw=2%26rank=3. Accessed 10 July 2022.
Matsuoka K, Naganuma M, Hibi T, Tsubouchi H, Oketani K, Katsurabara T, et al. Phase 1 study on the safety and efficacy of E6011, antifractalkine antibody, in patients with Crohn’s disease. J Gastroenterol Hepatol. 2021;36(8):2180–6. https://doi.org/10.1111/jgh.15463
Danese S, Neurath M, Kopon A, Zakko S, Simmons T, Fogel R, et al. OP006 Apremilast for active ulcerative colitis: a phase 2, randomised, double-blind, placebo-controlled induction study. J Crohn’s Colitis. 2018;12(Suppl):S004–5. https://doi.org/10.1093/ecco-jcc/jjx180.004
Phase II study of Hemay007 in patients with active ulcerative colitis - full text view. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03977480. Accessed 4 August 2022.
Boden EK, Canavan JB, Moran CJ, McCann K, Dunn WA, Farraye FA, et al. Immunologic alterations associated with oral delivery of anti-CD3 (OKT3) monoclonal antibodies in patients with moderate-to-severe ulcerative colitis. Crohn’s Colitis 360. 2019;1(2). https://doi.org/10.1093/crocol/otz009
A study to investigate how well ravagalimab (ABBV-323) works and how safe it is in participants with moderate to severe ulcerative colitis who failed prior therapy - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT03695185?cond=ABBV-323%26draw=2%26rank=1. Accessed 10 July 2022.
Rubin DT, Lee SD, Flores L, Albizu-Angulo G, Scherl EJ, Saini S, et al. A phase II open label study of neihulizumab, anti-CD125 (PSGL-1) antibody, in patients with moderately to severely active, anti-TNF alpha and/or anti-intergrin refractory ulcerative colitis n.d.
A phase 2 safety and efficacy study of PRA023 in subjects with moderately to severely active ulcerative colitis - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT04996797?cond=PRA023%26draw=2%26rank=5. Accessed 11 July 2022.
A phase 2a safety and efficacy open-label study of PRA023 in subjects with moderately to severely active Crohn’s disease - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT05013905?cond=PRA023%26draw=2%26rank=3. Accessed 11 July 2022.
Vermeire S, Hébuterne X, Tilg H, De Hertogh G, Gineste P, Steens JM. Induction and long-term follow-up with ABX464 for moderate-to-severe ulcerative colitis: results of phase IIa trial. Gastroenterology. 2021;160(7):2595–8. e3. https://doi.org/10.1053/j.gastro.2021.02.054
Long-term safety and efficacy profile of ABX464 in subjects with moderate to severe active ulcerative colitis - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT05177835?cond=ABX464%26draw=2%26rank=11. Accessed 11 July 2022.
Dose-ranging phase 2b study of ABX464 in moderate to severe ulcerative colitis - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT03760003?cond=ABX464%26draw=2%26rank=7. Accessed 11 July 2022.
ABX464 in subjects with moderate to severe active ulcerative colitis - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT03093259?cond=ABX464%26draw=2%26rank=5. Accessed 11 July 2022.
Study evaluating the long-term safety and efficacy of ABX464 in active ulcerative colitis - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT03368118?cond=ABX464%26draw=2%26rank=3. Accessed 11 July 2022.
An open-label, proof of consent study of vorinostat for the treatment of mdoerate-to-severe Crohn s disease and maintenance therapy with ustekinumab - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT03167437?cond=Vorinostat+crohn%26draw=2%26rank=1. Accessed 11 July 2022.
Scheibe K, Kersten C, Schmied A, Vieth M, Primbs T, Carlé B, et al. Inhibiting interleukin 36 receptor signaling reduces fibrosis in mice with chronic intestinal inflammation. Gastroenterology. 2019;156(4):1082–97. e11. https://doi.org/10.1053/j.gastro.2018.11.029
Nishida A, Inatomi O, Fujimoto T, Imaeda H, Tani M, Andoh A. Interleukin-36α induces inflammatory mediators from human Pancreatic myofibroblasts via a MyD88 dependent pathway. Pancreas. 2017;46(4):539–48. https://doi.org/10.1097/MPA.0000000000000765
A study to test whether spesolimab helps people with Crohn’s disease who have symptoms of bowel obstruction - full text view. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05013385?cond=spesolimab%26draw=2%26rank=2. Accessed 3 August 2022.
A study to test long-term treatment with spesolimab in patients with fistulising Crohn’s disease who took part in previous trials - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT04362254?cond=Spesolimab%26draw=1%26rank=5. Accessed 10 July 2022.
A study testing how BI 655130 works in patients with fistulizing Crohn’s disease - full text view. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03752970?cond=BI655130%26draw=2%26rank=5. Accessed 5 August 2022.
Santacroce G, Lenti MV, Di Sabatino A. Therapeutic targeting of intestinal fibrosis in crohn’s disease. Cells. 2022;11(3):429. https://doi.org/10.3390/CELLS11030429
Chang JT. Pathophysiology of inflammatory bowel diseases. N Engl J Med. 2020;383(27):2652–64. https://doi.org/10.1056/NEJMRA2002697
Stalgis C, Deepak P, Mehandru S, Colombel JF. Rational combination therapy to overcome the plateau of drug efficacy in inflammatory bowel disease. Gastroenterology. 2021;161(2):394–9. https://doi.org/10.1053/j.gastro.2021.04.068
Privitera G, Pugliese D, Onali S, Petito V, Scaldaferri F, Gasbarrini A, et al. Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy. Autoimmun Rev. 2021;20(6):102832. https://doi.org/10.1016/J.AUTREV.2021.102832
Sands BE, Feagan BG, Sandborn WJ, Shipitofsky N, Marko M, Sheng S, et al. OP36 Efficacy and safety of combination induction therapy with guselkumab and golimumab in participants with moderately-to-severely active Ulcerative Colitis: results through week 12 of a phase 2a randomized, double-blind, active-controlled, parallel-grou. J Crohn’s Colitis. 2022;16(Suppl 1):i042–3. https://doi.org/10.1093/ecco-jcc/jjab232.035
A study of combination therapy with guselkumab and golimumab in participants with moderately to severely active ulcerative colitis (DUET-UC). https://www.clinicaltrials.gov/ct2/show/NCT05242484?cond=NCT05242484%26draw=2%26rank=1. Accessed 11 July 2022.
A study of combination therapy with guselkumab and golimumab in participants with moderately to severely active Crohn’s disease (DUET-CD). https://www.clinicaltrials.gov/ct2/show/NCT05242471?cond=NCT05242471%26draw=2%26rank=1. Accessed 11 July 2022.
A study to evaluate adverse events and change in disease activity in participants between 18 to 75 Years of age treated with intravenous (IV) infusion and subcutaneous (SC) injections of ABBV-154 for moderately to severely active Crohn’s disease - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT05068284?cond=ABBV-154%26draw=2%26rank=1. Accessed 11 July 2022.
A study to test whether BI 706321 combined with ustekinumab helps people with Crohn’s disease - full text view. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT04978493?cond=BI+706321%26draw=2%26rank=4. Accessed 11 July 2022.
A study in patients with mild or moderate ulcerative colitis who take a TNF inhibitor. The study investigates whether bowel inflammation improves when patients take BI 655130 in addition to their current therapy - full text view. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03123120?cond=BI655130%26draw=2%26rank=19. Accessed 5 August 2022.
Triple combination therapy in high risk Crohn’s disease (CD) - full text view. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02764762?cond=NCT02764762%26draw=2%26rank=1. Accessed 5 August 2022.
Danese S, Solitano V, Jairath V, Peyrin-Biroulet L. The future of drug development for inflammatory bowel disease: the need to ACT (advanced combination treatment). Gut. 2022:327025. https://doi.org/10.1136/gutjnl-2022-327025
Vermeire S, O’Byrne S, Keir M, Williams M, Lu TT, Mansfield JC, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet. 2014;384(9940):309–18. https://doi.org/10.1016/S0140-6736(14)60661-9
Sandborn WJ, Feagan BG, Wolf DC, D’Haens G, Vermeire S, Hanauer SB, et al. Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med. 2016;374(18):1754–62. https://doi.org/10.1056/nejmoa1513248
Sandborn WJ, Feagan BG, Hanauer S, Vermeire S, Ghosh S, Liu WJ, et al. Long-term efficacy and safety of ozanimod in moderately to severely active ulcerative colitis: results from the open-label extension of the randomized, phase 2 TOUCHSTONE study. J Crohn’s Colitis. 2021;15(7):1120–9. https://doi.org/10.1093/ecco-jcc/jjab012
Atreya R, Peyrin-Biroulet L, Klymenko A, Augustyn M, Bakulin I, Slankamenac D, et al. Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial. Lancet Gastroenterol Hepatol. 2020;5(12):1063–75. https://doi.org/10.1016/S2468-1253(20)30301-0
Chen B, Zhang S, Wang B, Chen H, Li Y, Cao Q, et al. 775b olamkicept, an IL-6 trans-signaling inhibitor, is effective for induction of response and remission in A randomized, placebo-controlled trial in moderate to severe ulcerative colitis. Gastroenterology. 2021;161(2):e28–9. https://doi.org/10.1053/j.gastro.2021.06.038
Danese S, Vermeire S, Hellstern P, Panaccione R, Rogler G, Fraser G, et al. Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II). Gut. 2019;68(1):40–8. https://doi.org/10.1136/gutjnl-2017-314562
Rovedatti L, Kudo T, Biancheri P, Sarra M, Knowles CH, Rampton DS, et al. Differential regulation of interleukin 17 and interferon γ production in inflammatory bowel disease. Gut. 2009;58(12):1629–36. https://doi.org/10.1136/gut.2009.182170
Neufert C, Neurath MF, Atreya R. Rationale for IL-36 receptor antibodies in ulcerative colitis. Expert Opin Biol Ther. 2020;20(4):339–42. https://doi.org/10.1080/14712598.2020.1695775
Tchao N, Amouzadeh H, Sarkar N, Chow V, Hu X, Kroenke M, et al. Efavaleukin alfa, a novel IL-2 mutein, selectively expands regulatory T cells in patients with SLE: interim results of a phase 1b multiple ascending dose study - ACR meeting abstracts. Efavaleukin alfa, a novel IL-2 mutein, selectively expands regulatory T cells in patients with SLE: interim results of a phase 1b multiple ascending dose study. https://acrabstracts.org/abstract/efavaleukin-alfa-a-novel-il-2-mutein-selectively-expands-regulatory-t-cells-in-patients-with-sle-interim-results-of-a-phase-1b-multiple-ascending-dose-study/. Accessed 6 July 2022.
Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R. IL-22 increases the innate immunity of tissues. Immunity. 2004;21(2):241–54. https://doi.org/10.1016/j.immuni.2004.07.007
Rothenberg ME, Wang Y, Lekkerkerker A, Danilenko DM, Maciuca R, Erickson R, et al. Randomized phase I healthy volunteer study of UTTR1147A (IL-22Fc): a potential therapy for epithelial Injury. Clin Pharmacol Ther. 2019;105(1):177–89. https://doi.org/10.1002/cpt.1164
Hassan-Zahraee PhD M, Ye Z, Xi L, Banerjee A, He W, Dushin E, et al. DOP80 Integrated tissue transcriptomic and serum proteomic interrogation reveals biomarkers for endoscopic improvement and histologic remission after JAK3/TEC inhibition in Ulcerative Colitis (UC) (Phase 2b Vibrato study). J Crohn’s Colitis. 2022;16(Suppl 1):i124. https://doi.org/10.1093/ecco-jcc/jjab232.119
Allende ML, Dreier JL, Mandala S, Proia RL. Expression of the sphingosine 1-phosphate receptor, S1P1, on T-cells controls thymic emigration. J Biol Chem. 2004;279(15):15396–401. https://doi.org/10.1074/jbc.M314291200
Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 2004;427(6972):355–60. https://doi.org/10.1038/nature02284
Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997;385(6617):640–2. https://doi.org/10.1038/385640a0
Forster K, Goethel A, Chan CWT, Zanello G, Streutker C, Croitoru K. An oral CD3-specific antibody suppresses T-cell-induced colitis and alters cytokine responses to T-cell activation in mice. Gastroenterology. 2012;143(5):1298–307. https://doi.org/10.1053/j.gastro.2012.07.019
Prehn JL, Mehdizadeh S, Landers CJ, Luo X, Cha SC, Wei P, et al. Potential role for TL1A, the new TNF-family member and potent costimulator of IFN-γ, in mucosal inflammation. Clin Immunol. 2004;112(1):66–77. https://doi.org/10.1016/j.clim.2004.02.007
Zheng L, Zhang X, Chen J, Ichikawa R, Wallace K, Pothoulakis C, et al. Sustained TL1A (TNFSF15) expression on both lymphoid and myeloid cells leads to mild spontaneous intestinal inflammation and fibrosis. Eur J Microbiol Immunol. 2013;3(1):11–20. https://doi.org/10.1556/eujmi.3.2013.1.2
Danese S, Klopocka M, Scherl EJ, Romatowski J, Allegretti JR, Peeva E, et al. Anti-TL1A antibody PF-06480605 safety and efficacy for ulcerative colitis: a phase 2a single-arm study. Clin Gastroenterol Hepatol. 2021;19(11):2324–32. e6. https://doi.org/10.1016/j.cgh.2021.06.011
Rowley A, Taylor M, Duggal A, Foster M, Sirohi S, Solanke Y, et al. P359 A novel phase 1 trial design to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of TOP1288, a narrow spectrum kinase inhibitor, delivered topically to the colon via oral administration. J Crohn’s Colitis. 2018;12(Suppl 1):S285–6. https://doi.org/10.1093/ecco-jcc/jjx180.486
Gantke T, Sriskantharajah S, Ley SC. Regulation and function of TPL-2, an IB kinase-regulated MAP kinase kinase kinase. Cell Res. 2011;21(1):131–45. https://doi.org/10.1038/cr.2010.173
Edwards AJP, Pender SLF. Histone deacetylase inhibitors and their potential role in inflammatory bowel diseases, Biochem Soc Trans 39. Portland Press; 2011. p. 1092–5.
Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83(12):1583–90. https://doi.org/10.1016/j.bcp.2012.01.001
Lu Y, Li X, Liu S, Zhang Y, Zhang D. Toll-like receptors and inflammatory bowel disease. Front Immunol. 2018;72. https://doi.org/10.3389/fimmu.2018.00072
Furihata K, Ishiguro Y, Yoshimura N, Ito H, Katsushima S, Kaneko E, et al. A phase 1 study of KHK4083: a single-blind, randomized, placebo-controlled single-ascending-dose study in healthy adults and an open-label multiple-dose study in patients with ulcerative colitis. Clin Pharmacol Drug Dev. 2021;10(8):870–83. https://doi.org/10.1002/cpdd.918
Landos biopharma announces first patient dosed in a phase 1b study of NX-13 for ulcerative colitis, Landos biopharma. https://ir.landosbiopharma.com/news-releases/news-release-details/landos-biopharma-announces-first-patient-dosed-phase-1b-study-nx/. Accessed 13 July 2022.
Leber A, Hontecillas R, Zoccoli-Rodriguez V, Colombel JF, Chauhan J, Ehrich M, et al. The safety, tolerability, and pharmacokinetics profile of BT-11, an oral, gut-restricted Lanthionine synthetase C-like 2 agonist investigational new drug for inflammatory bowel disease: a randomized, double-blind, placebo-controlled phase i clinical trial. Inflamm Bowel Dis. 2020;26(4):643–52. https://doi.org/10.1093/ibd/izz094
Garg M, Burrell LM, Velkoska E, Griggs K, Angus PW, Gibson PR, et al. Upregulation of circulating components of the alternative renin-angiotensin system in inflammatory bowel disease: a pilot study. J Renin-Angiotensin-Aldosterone Syst. 2015;16(3):559–69. https://doi.org/10.1177/1470320314521086
Vadstrup K, Bendtsen F. Anti-NKG2D mAb: a new treatment for crohn’s disease? Int J Mol Sci. 2017;18(9):1997. https://doi.org/10.3390/ijms18091997
Yadav V, Mai Y, McCoubrey LE, Wada Y, Tomioka M, Kawata S, et al. 5-aminolevulinic acid as a novel therapeutic for inflammatory bowel disease. Biomedicines. 2021;9(5):578. https://doi.org/10.3390/biomedicines9050578
Iacucci M, De Silva S, Ghosh S. Mesalazine in inflammatory bowel disease: a trendy topic once again? Can J Gastroenterol. 2010;24(2):127–33. https://doi.org/10.1155/2010/586092
Fiorino G, Sturniolo GC, Bossa F, Cassinotti A, Di Sabatino A, Giuffrida P, et al. A phase 2a, multicenter, randomized, double-blind, parallel-group, placebo-controlled trial of IBD98-M delayed-release capsules to induce remission in patients with active and mild to moderate ulcerative colitis. Cells. 2019;8(6):523. https://doi.org/10.3390/CELLS8060523
Harris MS, Hartman D, Lemos BR, Erlich EC, Spence S, Kennedy S, et al. AVX-470, an orally delivered anti-tumour necrosis factor antibody for treatment of active ulcerative colitis: results of a first-in-human trial. J Crohn’s Colitis. 2016;10(6):631–40. https://doi.org/10.1093/ecco-jcc/jjw036
Nurbhai S, Roberts KJ, Carlton TM, Maggiore L, Cubitt MF, Ray KP, et al. Oral anti-tumour necrosis factor domain antibody V565 provides high intestinal concentrations, and reduces markers of inflammation in ulcerative colitis patients. Sci Rep. 2019;9(1):14042. https://doi.org/10.1038/s41598-019-50545-x
Atreya R, Kuehbacher T, Schmitt H, Hirschmann S, Waldner M, Drvarov O, et al. 817 - topical administration of a Gata-3 specific dnazyme suppresses mucosal inflammation in a randomized trial with moderate-to-severe ulcerative colitis patients. Gastroenterology. 2018;154(6):S-169. https://doi.org/10.1016/s0016-5085(18)30975-2
Kim WK, Han DH, Jang YJ, Park S, Jang SJ, Lee G, et al. Alleviation of DSS-induced colitis: via Lactobacillus acidophilus treatment in mice. Food Funct. 2021;12(1):340–50. https://doi.org/10.1039/d0fo01724h
Sandborn WJ, Elliott DE, Weinstock J, Summers RW, Landry-Wheeler A, Silver N, et al. Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn’s disease. Aliment Pharmacol Ther. 2013;38(3):255–63. https://doi.org/10.1111/apt.12366
Foligné B, Plé C, Titécat M, Dendooven A, Pagny A, Daniel C, et al. Contribution of the gut microbiota in p28gstmediated anti-inflammatory effects: experimental and clinical insights. Cells. 2019;8(6):577. https://doi.org/10.3390/cells8060577
Graham DY, Hardi R, Welton T, Krause R, Levenson S, Sarles H, et al. Phase III randomized, double blind, placebocontrolled, multicenter, parallel group study to assess the efficacy and safety of add-on fixed-dose anti-mycobacterial therapy (RHB-104) in moderately to severely active Crohn’s disease (MAP US). United Eur Gastroenterol J. 2018;6:1589–90.
Silber J, Norman J, Kanno T, Crossette E, Szabady R, Menon R, et al. Randomized, double-blind, placebo (pbo)-controlled, single- and multiple-dose phase 1 study of ve202, a defined bacterial consortium for treatment of ibd: safety and colonization dynamics of a novel live biotherapeutic product (lbp) in healthy adults. Inflamm Bowel Dis. 2022;28(Suppl 1):S65–6. https://doi.org/10.1093/ibd/izac015.106
